Your browser doesn't support javascript.
loading
Treatment of pyoderma gangrenosum: A multicenter survey-based study assessing satisfaction and quality of life.
Hobbs, Misty M; Byler, Rebecca; Latour, Emile; Bonomo, Lauren; Hennessy, Kerry; Cruz-Diaz, Carla N; Shinohara, Michi M; Seminario-Vidal, Lucia; Shinkai, Kanade; Ortega-Loayza, Alex G.
Afiliação
  • Hobbs MM; Department of Dermatology, Mayo Clinic, Jacksonville, Florida, USA.
  • Byler R; Department of Biomedical Engineering, Yale University, New Haven, Connecticut, USA.
  • Latour E; Oregon Health & Science University, Biostatistics Shared Resource, Knight Cancer Institute, Portland, Oregon, USA.
  • Bonomo L; Division of Dermatology, University of Washington, Seattle, Washington, USA.
  • Hennessy K; Department of Dermatology and Cutaneous Surgery, University of South Florida, Tampa, Florida, USA.
  • Cruz-Diaz CN; Department of Dermatology, University of California San Francisco, San Francisco, California, USA.
  • Shinohara MM; Division of Dermatology, University of Washington, Seattle, Washington, USA.
  • Seminario-Vidal L; Department of Dermatology and Cutaneous Surgery, University of South Florida, Tampa, Florida, USA.
  • Shinkai K; Department of Dermatology, University of California San Francisco, San Francisco, California, USA.
  • Ortega-Loayza AG; Department of Dermatology, Oregon Health and Science University, Portland, Oregon, USA.
Dermatol Ther ; 34(2): e14736, 2021 03.
Article em En | MEDLINE | ID: mdl-33394563
ABSTRACT
Pyoderma gangrenosum (PG) lacks consensus regarding treatment, and no prior studies assess treatment satisfaction in PG. The objective of this study was to determine patient-reported satisfaction in the treatment of PG, and associations with satisfaction. Methodology was a multicenter cross-sectional survey for patients who received systemic medication(s) to treat PG. Thirty-five patients completed the survey (mean age 54.0 years, 65.7% female, response rate 81.4%). Mean (± SD) SATMED-Q score was 75.0 (±16.2, range 67.6-85.3). Older patients (72.6 ± 23.6 for 18-39 years, 74.4 ± 16.1 for 40-59, 77.1 ± 11.6 for 60+), plus those with higher incomes (72.9 ± 20.3 for $0-49 000; 74.0 ± 17.6 for $50 000-99 000; 79.0 ± 14.6 for $100 000+) and education status (69.4 ± 14.3 for high school equivalent, 72.9 ± 15.9 for undergraduate, 91.7 ± 10.6 for graduate), were more satisfied with treatment. Ulcerative PG had higher SATMED-Q scores (79.0 ± 13.2) than other subtypes (66.2 ± 19.3). For local therapy, wound care, or pain control, 63.2%, 100%, and 75% were satisfied, respectively. The mean DLQI was 8.6 (±7.6, range 0-29), and higher DLQI was associated with decreased satisfaction. Satisfaction with providers was positively correlated with global satisfaction (Pearson's r = 0.638). The presence of pain and/or depression influenced both SATMED-Q (72.8 ± 18.8 with pain, 78.3 ± 11.2 without; 68.2 ± 18.8 with depression, 80.1 ± 12.2 without) and DLQI scores (12.1 ± 8.1 with pain, 3.9 ± 3.4 without; 10.3 ± 7.1 with depression, 7.4 ± 8.0 without). To optimize the patient experience, non-modifiable associations should be individually considered, and potentially modifiable associations such as satisfaction with specific providers, pain, and depression, may be targeted for management.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article